Mitchell S. Kapoor
Stock Analyst at HC Wainwright & Co.
(3.60)
# 814
Out of 5,135 analysts
75
Total ratings
44.12%
Success rate
9.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mitchell S. Kapoor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TYRA Tyra Biosciences | Maintains: Buy | $30 → $45 | $29.06 | +54.85% | 2 | Feb 17, 2026 | |
| INCY Incyte | Reiterates: Buy | $135 | $103.23 | +30.78% | 2 | Feb 11, 2026 | |
| EVMN Evommune | Maintains: Buy | $35 → $65 | $31.12 | +108.87% | 2 | Feb 10, 2026 | |
| SMMT Summit Therapeutics | Reiterates: Buy | $40 | $15.87 | +152.05% | 7 | Feb 2, 2026 | |
| KRRO Korro Bio | Upgrades: Buy | $20 | $11.32 | +76.68% | 3 | Jan 29, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $15 → $25 | $12.47 | +100.48% | 6 | Jan 28, 2026 | |
| SRPT Sarepta Therapeutics | Reiterates: Sell | $5 | $18.42 | -72.86% | 3 | Jan 27, 2026 | |
| LEGN Legend Biotech | Maintains: Buy | $60 → $50 | $18.64 | +168.24% | 2 | Jan 22, 2026 | |
| AVTX Avalo Therapeutics | Reiterates: Buy | $25 | $15.06 | +66.00% | 2 | Jan 15, 2026 | |
| NGNE Neurogene | Reiterates: Buy | $70 | $17.17 | +307.69% | 4 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $10 | $6.42 | +55.88% | 4 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 → $40 | $27.19 | +47.11% | 3 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.72 | - | 4 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $60 | $61.22 | -1.99% | 3 | Dec 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $90 | $72.64 | +23.90% | 5 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $20 → $45 | $24.32 | +85.07% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $7.54 | +165.25% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $30 | $6.27 | +378.47% | 1 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $10 | $5.21 | +91.94% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $110 | $82.52 | +33.30% | 6 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $20 | $7.71 | +159.40% | 2 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $40 | $32.26 | +23.99% | 2 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $53.32 | +50.04% | 1 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.74 | +187.36% | 2 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $9.61 | +160.15% | 2 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $1.48 | +372.97% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $2 | $6.26 | -68.05% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $1.16 | +244.83% | 1 | Aug 11, 2025 |
Tyra Biosciences
Feb 17, 2026
Maintains: Buy
Price Target: $30 → $45
Current: $29.06
Upside: +54.85%
Incyte
Feb 11, 2026
Reiterates: Buy
Price Target: $135
Current: $103.23
Upside: +30.78%
Evommune
Feb 10, 2026
Maintains: Buy
Price Target: $35 → $65
Current: $31.12
Upside: +108.87%
Summit Therapeutics
Feb 2, 2026
Reiterates: Buy
Price Target: $40
Current: $15.87
Upside: +152.05%
Korro Bio
Jan 29, 2026
Upgrades: Buy
Price Target: $20
Current: $11.32
Upside: +76.68%
Intellia Therapeutics
Jan 28, 2026
Maintains: Buy
Price Target: $15 → $25
Current: $12.47
Upside: +100.48%
Sarepta Therapeutics
Jan 27, 2026
Reiterates: Sell
Price Target: $5
Current: $18.42
Upside: -72.86%
Legend Biotech
Jan 22, 2026
Maintains: Buy
Price Target: $60 → $50
Current: $18.64
Upside: +168.24%
Avalo Therapeutics
Jan 15, 2026
Reiterates: Buy
Price Target: $25
Current: $15.06
Upside: +66.00%
Neurogene
Jan 13, 2026
Reiterates: Buy
Price Target: $70
Current: $17.17
Upside: +307.69%
Jan 13, 2026
Maintains: Buy
Price Target: $13 → $10
Current: $6.42
Upside: +55.88%
Jan 9, 2026
Reiterates: Buy
Price Target: $20 → $40
Current: $27.19
Upside: +47.11%
Jan 7, 2026
Downgrades: Neutral
Price Target: n/a
Current: $8.72
Upside: -
Dec 22, 2025
Maintains: Neutral
Price Target: $55 → $60
Current: $61.22
Upside: -1.99%
Dec 19, 2025
Reiterates: Buy
Price Target: $90
Current: $72.64
Upside: +23.90%
Dec 9, 2025
Upgrades: Buy
Price Target: $20 → $45
Current: $24.32
Upside: +85.07%
Nov 24, 2025
Initiates: Buy
Price Target: $20
Current: $7.54
Upside: +165.25%
Nov 19, 2025
Maintains: Buy
Price Target: $40 → $30
Current: $6.27
Upside: +378.47%
Nov 11, 2025
Maintains: Buy
Price Target: $5 → $10
Current: $5.21
Upside: +91.94%
Nov 10, 2025
Maintains: Buy
Price Target: $100 → $110
Current: $82.52
Upside: +33.30%
Oct 27, 2025
Maintains: Buy
Price Target: $10 → $20
Current: $7.71
Upside: +159.40%
Oct 27, 2025
Maintains: Buy
Price Target: $45 → $40
Current: $32.26
Upside: +23.99%
Sep 23, 2025
Reiterates: Buy
Price Target: $80
Current: $53.32
Upside: +50.04%
Sep 5, 2025
Reiterates: Buy
Price Target: $5
Current: $1.74
Upside: +187.36%
Aug 27, 2025
Reiterates: Buy
Price Target: $25
Current: $9.61
Upside: +160.15%
Aug 19, 2025
Reiterates: Buy
Price Target: $7
Current: $1.48
Upside: +372.97%
Aug 19, 2025
Maintains: Neutral
Price Target: $3 → $2
Current: $6.26
Upside: -68.05%
Aug 11, 2025
Maintains: Buy
Price Target: $5 → $4
Current: $1.16
Upside: +244.83%